Mosaic's second quarter became a textbook case of how a commodity producer can lose money while selling more of its product. The quarter closed with a net loss of $272.8 million, or $(0.86) per diluted share. A year earlier Mosaic earned $410.7 million. The gap was not primarily a price story. Phosphate average selling prices rose about 13% year on year, while potash prices were higher too. The gross margin collapsed, falling 59% to $214.7 million, as the cost of sulfur, ammonia and blended rock surged with the Middle East conflict and the resulting tightening of fertilizer supply chains. A year earlier the gross margin was $518.6 million. Cost of goods sold for the half year rose 16%. That math is the central event of the quarter.
The market has read the result accordingly. Shares trade near $25.78 against a fifty-two-week range topping out near $36.99. The market capitalization is roughly $8.2 billion. The dividend yield is about 3.55% on the $0.22 quarterly payout, and that yield is the one support that has not wavered through the worst quarter Mosaic has reported in years. Trailing twelve months remain in a loss, and the next twelve months trade on a forward multiple of roughly 16x, which is the multiple a recovery would justify rather than the multiple the current cycle is producing. A book value of $11.5 billion against an $8.2 billion market cap leaves the equity trading well below replacement value, a setup that historically marks either the bottom of a fertilizer cycle or a structural impairment the market is correctly anticipating. The enterprise value sits near $13.8 billion, an EV-to-EBITDA multiple of roughly 8x that already reflects the cycle still in the run-up rather than the cycle already turning. The disconnect between the equity's recovery multiple and the quarter's loss-making print is the central valuation question for the back half of the year.
Three forces shape the next chapter: the trajectory of sulfur and ammonia input prices, the speed at which Mosaic can restart the idled Brazilian complexes, and the mark-to-market path of the Ma'aden stake. The bull case rests on the conviction that sulfur normalizes and that the divested Brazilian assets stop dragging. The bear case rests on the visible evidence that phosphate rock costs in North America rose 22% year on year, and that Brazilian rock production fell more than 30% in the quarter. The most important counterargument to the bear case is that the quarter's worst items are concentrated in the things the company itself can change, which is the asymmetry the dividend is funding. The most useful single forward number to anchor against is sulfur: each 10% normalization in the consumed sulfur price moves the phosphate gross margin by roughly $50 million, and that scale is what makes the recovery thesis quantitative rather than aspirational.